VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients aged 19 or older                          │ Patients aged 19 or older                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have submitted a written consent to   │ Patients who have submitted a written consent to   │     100 │
│ participate in the clinical trial                  │ participate in the clinical trial                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ De novo lesion                                     │ De novo lesion                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients scheduled for elective intervention to    │ Patients scheduled for elective intervention to    │     100 │
│ treat ischemic cardiovascular disease              │ treat ischemic cardiovascular disease              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with any contraindications or             │ Patients with any contraindications or             │     100 │
│ hypersensitivity related to antiplatelet therapy   │ hypersensitivity related to antiplatelet therapy   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with Acute Myocardial Infarction (ST      │ Patients with Acute Myocardial Infarction (ST      │     100 │
│ elevation myocardial infarction, Non ST elevation  │ elevation myocardial infarction, Non ST elevation  │         │
│ myocardial infarction)                             │ myocardial infarction)                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are anticipated to receive treatment  │ Patients who are anticipated to receive treatment  │     100 │
│ or surgery that may require desisting the          │ or surgery that may require desisting the          │         │
│ administration of antiplatelet therapy for 2 weeks │ administration of antiplatelet therapy for 2 weeks │         │
│ or longer during the period of the clinical trial  │ or longer during the period of the clinical trial  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic total occlusion (CTO) lesions, in-stent    │ Chronic total occlusion (CTO) lesions, in-stent    │     100 │
│ restenosis (ISR)                                   │ restenosis (ISR)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients experiencing cardiogenic shock            │ Patients experiencing cardiogenic shock            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are breastfeeding, pregnant, or desiring │ Women who are breastfeeding, pregnant, or desiring │     100 │
│ pregnancy                                          │ pregnancy                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with findings of hemorrhage               │ Patients with findings of hemorrhage               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a life expectancy of less than 1     │ Patients with a life expectancy of less than 1     │     100 │
│ year                                               │ year                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have received a drug-eluting stent    │ Patients who have received a drug-eluting stent    │     100 │
│ (DES) procedure within the past 6 months           │ (DES) procedure within the past 6 months           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other patients judged by the investigator to   │ Any other patients judged by the investigator to   │     100 │
│ be unsuitable for the trial                        │ be unsuitable for the trial                        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Your personal trial has no unique criteria

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 100
Average Levenshtein Ratio of individual lines: 100.0
OverAll Ratio: 100.0
